The effect of lamotrigine and phenytoin on bone turnover and bone strength: A prospective study in Wistar rats

Epilepsy Research

Volumn 128, Issue , 2016, Pages 113-118

  Simko, Julius ^a   Karesova, Iva ^b   Kremlacek, Jan ^a   Fekete, Sona ^b   Zimcikova, Eva ^c   Malakova, Jana ^b   Zivna, Helena ^a   Valis, Martin ^a   Palicka, Vladimir ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Amino terminal propeptide of procollagen type I; Bone alkaline phosphatase; Bone mineral density; Bone turnover markers; Osteoprotegerin receptor activator of nuclear factor kappa B ratio; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; LAMOTRIGINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SCLEROSTIN; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; PHENYTOIN; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE METABOLISM; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMORAL NECK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; TISSUE HOMOGENATE; ANIMAL; BONE; BONE REMODELING; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; LONGITUDINAL STUDY; METABOLISM; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; WISTAR RAT;

ABSORPTIOMETRY, PHOTON; ANIMALS; ANTICONVULSANTS; BIOMARKERS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY; BONE REMODELING; LONGITUDINAL STUDIES; MALE; PHENYTOIN; PROSPECTIVE STUDIES; RATS, WISTAR; TRIAZINES;

EID: 84994663327     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2016.10.005     Document Type: Article

References (31)

1. Adams, J., Vorhees, C.V., Middaugh, L.D., Developmental neurotoxicity of anticonvulsants: human and animal evidence on phenytoin. Neurotoxicol. Teratol. 12 (1990), 203–214.
2. Anderson, G.D., Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurol 63 (2004), S3–S8.
3. Babacan, O., Karaoglu, A., Vurucu, S., et al. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism?. J. Clin. Neurol. 8 (2012), 65–68.
4. Brodie, M.J., Mintzer, S., Pack, A.M., et al. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 54 (2013), 11–27.
5. Carbone, L.D., Johnson, K.C., Robbins, J., et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J. Bone Miner. Res. 25 (2010), 873–881.
6. Coppola, G., Fortunato, D., Auricchio, G., et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 50 (2009), 2140–2146.
7. Elwakkad, A.S., El Elshamy, K.A., Sibaii, H., Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats. Epilepsy Res. 80 (2008), 47–56.
8. Ensrud, K.E., Walczak, T.S., Blackwell, T.L., et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurol 71 (2008), 723–730.
9. Gradosova, I., Zivna, H., Svejkovska, K., Palicka, V., Tichy, A., Zivny, P., The role of atorvastatin in bone metabolism in male albino Wistar rats. Pharmazie 66 (2011), 606–610.
10. Guo, C.Y., Ronen, G.M., Atkinson, S.A., Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 (2001), 1141–1147.
11. Hamed, S.A., Moussa, E.M., Youssef, A.H., et al. Bone status in patients with epilepsy: relationship to markers of bone remodeling. Front. Neurol., 5, 2014, 142.
12. Heo, K., Rhee, Y., Lee, H.W., et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 52 (2011), 1884–1889.
13. Hofbauer, L.C., Schoppet, M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 490 (2004), 490–495.
14. Kim, S.H., Lee, J.W., Choi, K.G., et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 10 (2007), 291–295.
15. Kruse, R., Osteopathien bei antioepileptischer Langzeittherapie. Mschr. Kinderheilk., 1, 1968.
16. Malakova, J., Brozmanova, H., Vorisek, V., et al. A capillary GC method using nitrogen phosphorus detection for determination of topiramate in patients with epilepsy. Chromatographia 66 (2007), 363–367.
17. Mikulecká, A., Kubová, H., Mareš, P., Lamotrigine does not impair motor performance and spontaneous behavior in developing rats. Epilepsy Behav. 5 (2004), 464–471.
18. Mintzer, S., Boppana, P., Toguri, J., et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47 (2006), 510–515.
19. Nissen-Meyer, L.S., Svalheim, S., Taubøll, E., et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 48 (2007), 1850–1860.
20. Ohta, T., Wergedal, J.E., Gruber, H.E., et al. Low dose phenytoin is an osteogenic agent in the rat. Calcif. Tissue Int. 56 (1995), 42–48.
21. Pack, A., Bone health in people with epilepsy: is it impaired and what are the risk factors. Seizure 17 (2008), 181–186.
22. Pack, A.M., Morrell, M.J., Marcus, R., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann. Neurol. 57 (2005), 252–257.
23. Pack, A.M., Morrell, M.J., Randall, A., et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurol 70 (2008), 1586–1593.
24. Pagani, F., Francucci, C.M., Moro, L., Markers of bone turnover: biochemical and clinical perspectives. J. Endocrinol. Invest. 28 (2005), 8–13.
25. Schmid, F., Osteopathien bei antiepileptischer Dauerbehandlung. Fortschr. Med. 38 (1967), 381–382.
26. Sengupta, P., The laboratory rat: relating its age with huma's. Int. J. Prev. Med. 4:6 (2013), 624–630.
27. Sheth, R.D., Hermann, B.P., Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr. Neurol. 37 (2007), 250–254.
28. Simko, J., Fekete, S., Gradosova, I., et al. The effect of topiramate and lamotrigine on rat bone mass, structure and metabolism. J. Neurol. Sci. 340 (2014), 80–85.
29. Takahashi, A., Onodera, K., Kamei, J., et al. Effects of chronic administration of zonisamide, an antiepileptic drug, on bone mineral density and their prevention with alfacalcidol in growing rats. J. Pharmacol. Sci. 91 (2003), 313–318.
30. Valsamis, H.A., Arora, S.K., Labban, B., et al. Antiepileptic drugs and bone metabolism. Nutr. Metab. (Lond.), 36, 2006.
31. Wijenayaka, A.R., Kogawa, M., Lim, H.P., et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One, 2011, e25900.